Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Sep;87(9):916-22.
doi: 10.1002/ajh.23174. Epub 2012 Apr 4.

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges

Nirali N Shah  1 , Ulrike Bacher, Terry Fry, Katherine R Calvo, Maryalice Stetler-Stevenson, Diane C Arthur, Roger Kurlander, Kristin Baird, Barbara Wise, Sergio Giralt, Michael Bishop, Nancy M Hardy, Alan S Wayne
Affiliations
Case Reports

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges

Nirali N Shah et al. Am J Hematol. 2012 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Algorithm for the evaluation and treatment of MDS after allogeneic hematopoietic stem cell transplantation
This algorithm provides general guidelines for the evaluation and treatment of MDS after allogeneic hematopoietic stem cell transplantation. MDS should be considered in the differential diagnosis of persistent cytopenias and/or macrocytosis that are not otherwise explained by medication effect or post-transplant complications. Diagnostic bone marrow aspirate and biopsy should be performed for morphologic evaluation and extra aspirate samples collected for possible additional studies as detailed below. If dysplasia, atypia and/or increased blasts are detected, samples should be sent for cytogenetic evaluation by means of chromosome banding analysis and/or FISH, flow cytometry, PCR studies specific to previously documented molecular markers of the underlying disease, and/or chimerism analysis. The origin of the MDS as either recipient- or donor- derived should be determined. In patients previously transplanted for AML/MDS, relapse is more likely than de novo donor-cell MDS. In patients transplanted for other conditions, donor-cell MDS is most likely. Methods for determining the origin of MDS include STR/VNTR PCR, real-time PCR, and XY-FISH (in sex mismatched transplants). Treatment options for MDS after alloHSCT include hypomethylating agents, DLI, second alloHSCT (from the original or a new donor), cytotoxic chemotherapy, high-dose therapy with autologous stem cell rescue, and lenalidomide (for those with 5q-deletion). Enrollment in clinical trials should be considered. The decision regarding the best treatment for an individual patient is dependent upon the origin of the MDS (recipient versus donor), the rapidity of disease progression to AML, cytogenetic abnormalities, and co-morbidities. Treatment options should be weighed carefully and individualized with close considerations of such factors. Specifically, the origin of MDS plays an important role in determining the best therapy. For example, DLI may be a reasonable first choice to manage relapsed MDS of recipient origin, whereas a therapeutic GVL effect would not be expected in donor-derived MDS and thus an alternative treatment would be preferred in that setting. Although some treatment options have curative potential (e.g., second alloHSCT), these may be associated with high risk of treatment-related mortality. In contrast, other approaches are less likely to be curative, however, they may offer reduced toxicity and higher likelihood of improved short-term quality of life.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bishop MR, Alyea EP, 3rd, Cairo MS, Falkenburg JH, June CH, Kroger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010;16:563–564. - PMC - PubMed
    1. Bishop MR, Alyea EP, 3rd, Cairo MS, Falkenburg JH, June CH, Kroger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011;17:443–454. - PMC - PubMed
    1. Rihani R, Bazzeh F, Faqih N, Sultan I. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer. 2010;116:4385–4394. - PubMed
    1. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, Grier HE, Link MP, Meyers PA, Perlman EJ, Rausen AR, Robison LL, Vietti TJ, Miser JS. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children’s Oncology Group. Blood. 2007;109:46–51. - PMC - PubMed
    1. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2007;49:894–900. - PubMed

Publication types

MeSH terms